Andrés Felipe Bejarano-Ramirez

Andrés Felipe Bejarano-Ramirez

Auto-generated profile, based on publicly available information

Andrés Felipe Bejarano-Ramirez

Fundación Santa Fe de Bogota

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2025 in Scientific Reports
Verified
Journal Article
Open access
ECErick Andrés Cantor
Erick Andrés Cantor
ABAndrés Felipe Bejarano-Ramírez
Andrés Felipe Bejarano-Ramírez
LZLaura Chacón Zambrano
Laura Chacón Zambrano
ITIván Camilo Triana
Iván Camilo Triana
HVHenry Alexander Vargas
Henry Alexander Vargas
RLRoció López
Roció López
Programmed cell death ligand 1 (PD-L1) has emerged as a key biomarker in determining both the progression and prognosis of gastric cancer (GC). Consequently, its detection through immunohistochemical (IHC) analysis is essential for guiding appropriate treatment selection. We conducted an analytical, observational study based on a five-year retrospective cohort of patients diagnosed with gastric cancer at a comprehensive oncology center in Colombia. All patients underwent immunohistochemistry (IHC) to assess PD-L1 expression and calculate the Combined Positive Score (CPS). The objective of this study was to compare the positivity detection rates between the 28-8 and 22C3 assays and to evaluate the concordance between them. A descriptive analysis of clinical and pathological variables was performed. Univariate analysis was used to determine the frequency of PD-L1 expression and CPS distribution. Kaplan-Meier survival analysis was applied and stratified by PD-L1 status. Concordance between the two assays was assessed using the kappa (κ) index. A total of 175 patients diagnosed with gastric cancer (GC) and tested for PD-L1 expression were included in the study. Complete pathological and IHC data were available for 155 patients. Among them, 39.4% were tested with the 28-8 assay, and 60.6% with the 22C3 assay. PD-L1 positivity was observed in 34.4% of cases using the 28-8 assay and in 28.7% using the 22C3 assay. Among patients with available follow-up data (n = 34), PD-L1 testing was performed using the 22C3 clone, with a positivity rate of 35.3%. In the subgroup analysis of patients tested with both antibodies (n = 20), 60% were PD-L1 positive. Within this subset, 25% had a CPS of 1-4, 16.7% had a CPS of 5-9, and 58.3% had a CPS ≥ 10. For the 22C3 assay specifically, PD-L1 positivity was observed in 40% of cases, with 37.5% having a CPS of 1-4 and 62.5% a CPS ≥ 10; notably, no cases in this group had a CPS of 5-9. The concordance rate between the 28-8 and 22C3 assays was 61%, as measured by the kappa index. The 28-8 clone identified a higher proportion of patients with PD-L1 expression compared to the 22C3 antibody. However, both assays demonstrated a concordance rate of 61%. In the study population, the subgroup with a Combined Positive Score (CPS) ≥ 10 was the most prevalent, suggesting that high PD-L1 expression is relatively common and potentially clinically relevant in this cohort.

1 April 2026 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
MTMateo Tamayo
Mateo Tamayo
NDNicolas Duque-Clavijo
Nicolas Duque-Clavijo
Astrid Berena Herrera LópezAstrid Berena Herrera López
Astrid Berena Herrera López
MEManuela Estrada-Schweineberg
Manuela Estrada-Schweineberg
ABAndres Felipe Bejarano
Andres Felipe Bejarano
BWBeatriz Wills
Beatriz Wills
Background: Lung cancer remains a critical global health concern, with a substantial fraction arising in never-smokers. Air pollution—including particulate matter (PM2.5, PM10), nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O3)—has been implicated in lung carcinogenesis; however, studies linking these exposures to molecular biomarkers in Hispanic populations remain scarce. This study aimed to evaluate the association between exposure to air pollutants and oncogenic mutations in non-small cell lung cancer (NSCLC) in Hispanic patients in Bogotá. Methods: A retrospective cohort study was conducted on 205 Hispanic patients diagnosed with NSCLC between 2015 and 2022 at a quaternary care hospital in Bogotá, Colombia. Lung cancer driver mutations [epidermal growth factor receptor mutations (EGFRm), anaplastic lymphoma kinase (ALK) rearrangement, and programmed death-ligand 1 (PD-L1) expression] were assessed by reverse transcription polymerase chain reaction and immunohistochemistry. The estimated individual-level exposure to air pollutants (PM2.5, PM10, NO2, SO2, O3, and CO) was assessed from Bogotá’s Air Monitoring Stations using an inverse distance weighted regression model. Adjusted logistic regression analyses evaluated associations between biomarkers and pollutants. Kaplan-Meier and Cox proportional hazards models examined survival outcomes. Results: Mean annual exposure to PM2.5 (15.9 µg/m3), PM10 (32.6 µg/m3), and NO2 (28.3 µg/m3) exceeded the thresholds recommended by the World Health Organization. EGFRm were identified in 24.9% of patients, ALK rearrangements in 12.2%, and PD-L1 expression ≥1% in 41.5% (≥50% in 5.4%). EGFRm was associated with increased exposure to PM2.5 and PM10 levels [PM2.5: odds ratio (OR) 2.49, 95% confidence interval (CI): 1.11–6.41; PM10: OR 1.54, 95% CI: 1.05–2.34]. NO2 was associated with increased PD-L1 expression (OR 1.83, 95% CI: 1.33–2.65). The 5-year overall survival (OS) rate was 29.0%. Increased exposure to PM2.5 [hazard ratio (HR) 1.72; 95% CI: 1.04–2.84] and SO2 (HR 1.69, 95% CI: 1.07–2.68) were associated with mortality. Conclusions: These results underscore the potential impact of air pollution on the molecular landscape and clinical outcomes of patients diagnosed with NSCLC, and they open new avenues for research in genetically admixed populations.

1 December 2024 in SN Comprehensive Clinical Medicine
Verified
Journal Article
Closed access
PDF file
JCJuliana Cantor-Niño
Juliana Cantor-Niño
NDNicolas Duque-Clavijo
Nicolas Duque-Clavijo
ABAndrés Felipe Bejarano-Ramirez
Andrés Felipe Bejarano-Ramirez
HVHenry Vargas
Henry Vargas
JSJavier Mauricio Segovia
Javier Mauricio Segovia
ECErick Cantor
Erick Cantor

28 August 2024 in Die Orthopädie
Verified
Journal Article
Closed access
PDF file
ECErick Andrés Cantor
Erick Andrés Cantor
JSJavier Mauricio Segovia
Javier Mauricio Segovia
SOSergio Osorio
Sergio Osorio
JSJohn Alejandro Murillo Silva
John Alejandro Murillo Silva
HVHenry Alexander Vargas
Henry Alexander Vargas
ABAndres Felipe Bejarano
Andres Felipe Bejarano

5 December 2024 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
JVJuan Manuel Vásquez-Jiménez
Juan Manuel Vásquez-Jiménez
ARAndres Felipe Bejarano Ramirez
Andres Felipe Bejarano Ramirez
ERErick Andres Cantor Rizo
Erick Andres Cantor Rizo
LPLuis Eduardo Pino
Luis Eduardo Pino
Actionable mutations in the epidermal growth factor receptor (EGFR) gene are prevalent in non-small cell lung cancer (NSCLC). The advent of targeted therapy using tyrosine kinase inhibitors (TKIs) has significantly improved patient outcomes. However, the eventual development of resistance poses a substantial challenge. Molecular profiling is essential for tailoring personalized treatment strategies. Case Description: A 61-year-old female patient with NSCLC harboring the L858R mutation in EGFR was initially treated with osimertinib, achieving a complete response. Nevertheless, at 26 months, the disease progressed with the emergence of the L718Q mutation in EGFR. Osimertinib was discontinued, and a regimen of chemoimmunotherapy combined with erlotinib was initiated. The patient achieved a second complete response and remained progression-free for 14 months. Discussion: The L718Q mutation is rare and confers resistance to osimertinib. However, as demonstrated in this case, the mutation may render the tumor susceptible to alternative treatments. Several case reports suggest modest efficacy with various drug combinations, including other TKIs, chemotherapy, and antiangiogenic agents. This case represents one of the longest progression-free survival periods reported in this context. This underscores the importance of re-evaluating molecular targets upon disease progression in EGFR-mutated non-small cell lung cancer (NSCLC).

23 September 2025 in Respirar
Verified
Journal Article
Open access
PDF file
ITIvan Triana
Ivan Triana
IHIsabel Hernández-Linares
Isabel Hernández-Linares
AAAngela Aguirre
Angela Aguirre
JRJairo Hildebrando Roa
Jairo Hildebrando Roa
OGOlga Milena García
Olga Milena García
LHLuis Gerardo García Herreros
Luis Gerardo García Herreros
Background: Lung cancer is frequently diagnosed in advanced stages and is currently the leading cause of cancer-related mortality worldwide. A multidisciplinary approach is crucial to optimize diagnosis, treatment and improve patient survival. Methods: A retrospective cohort analytical study over two time periods, including patients over 18 years old with early-stage lung adenocarcinoma treated at a high-complexity oncology center in Colombia. The exposure group (2021-2023) received multidisciplinary care, while the non-exposure group (2018-2020) was managed conventionally by individual specialists. The study aimed to compare clinical outcomes and treatment times between both groups. Statistical analysis was based on the distribution of variables. Results: A total of 34 patients were included. The multidisciplinary approach enabled earlier diagnosis of lung adenocarcinoma, increasing early-stage identification from 30% to 61% between 2018 and 2022. Additionally, the multidisciplinary group had a higher proportion of asymptomatic cases (54% vs. 32%) and a lower relapse rate (7% vs. 52%) compared to conventional management. Treatment initiation times were significantly reduced from 3.2 to 2.2 months (p < 0.05), and the time from pathology to treatment decreased to 30 days in the multidisciplinary group versus 85 days in the conventional group. Conclusions: The multidisciplinary approach reduced waiting times for the initiation of cancer treatment, increased treatment adherence and improved clinical outcomes.